Avalo Therapeutics Inc. Watch

EX-2.1

from 8-K 68 pages Agreement and Plan of Merger and Reorganization by and Among Avalo Therapeutics Inc., Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, Almatabio, Inc., and the Securityholders’ Representative Identified Herein Dated as of March 27, 2024

12/34/56

EX-2.1

from 8-K 37 pages Certain Information Identified With the Mark “(***)” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Asset Purchase Agreement

12/34/56

EX-2.1

from 425 65 pages Agreement and Plan of Merger and Reorganization by and Among Cerecor Inc. Genie Merger Sub, Inc. Second Genie Merger Sub, LLC and Aevi Genomic Medicine, Inc. Dated as of December 5, 2019 Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.1

from 8-K/A 65 pages Agreement and Plan of Merger and Reorganization by and Among Cerecor Inc. Genie Merger Sub, Inc. Second Genie Merger Sub, LLC and Aevi Genomic Medicine, Inc. Dated as of December 5, 2019 Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.1

from 425 65 pages Agreement and Plan of Merger and Reorganization by and Among Cerecor Inc. Genie Merger Sub, Inc. Second Genie Merger Sub, LLC and Aevi Genomic Medicine, Inc. Dated as of December 5, 2019 Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.1

from 8-K 65 pages Agreement and Plan of Merger and Reorganization by and Among Cerecor Inc. Genie Merger Sub, Inc. Second Genie Merger Sub, LLC and Aevi Genomic Medicine, Inc. Dated as of December 5, 2019 Agreement and Plan of Merger and Reorganization

12/34/56

EX-2.1

from 8-K 16 pages First Amendment to Asset Purchase Agreement

12/34/56

EX-2.1

from 8-K 136 pages Asset Purchase Agreement Dated as of October 10, 2019 Between Aytu Bioscience, Inc. and Cerecor Inc

12/34/56

EX-2.1

from 8-K 72 pages Agreement and Plan of Merger Among Cerecor, Inc., Itx Merger Sub, Inc., Second Itx Merger Sub, LLC, Ichorion Therapeutics, Inc., and David Maizenberg, as Holders’ Representative September 24, 2018

12/34/56

EX-2.1

from 424B3 53 pages Portions of This Exhibit Marked [*] Are Requested to Be Treated Confidentially. Asset Purchase Agreement Dated as of February 12, 2018 Between Cerecor, Inc. and Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., Fsc Therapeutics, LLC, Avadel US Holdings, Inc. and Avadel Pharmaceuticals PLC

12/34/56

EX-2.1

from 10-Q 53 pages Portions of This Exhibit Marked [*] Are Requested to Be Treated Confidentially. Asset Purchase Agreement Dated as of February 12, 2018 Between Cerecor, Inc. and Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., Fsc Therapeutics, LLC, Avadel US Holdings, Inc. and Avadel Pharmaceuticals PLC

12/34/56

EX-2.2

from 8-K 54 pages Agreement and Plan of Merger and Reorganization by and Among Cerecor Inc., Zpc Merger Corp. Zylera Pharma Corp. Zylera Pharmaceuticals, LLC and the Sellers Named Herein Dated as of November 17, 2017

12/34/56

EX-2.1

from 8-K 72 pages Equity Interest Purchase Agreement by and Among Cerecor Inc., Trx Pharmaceuticals, LLC, the Sellers Named Herein and Randal Jones and Robert Moscato (Solely for Purposes of Section 6.2 Hereof) Dated as of November 17, 2017

12/34/56

EX-2.1

from 8-K 49 pages Asset Purchase Agreement Dated as of August 14, 2017 Between Janssen Pharmaceuticals, Inc. and Cerecor Inc

12/34/56